Pharmaceutical Dissolution Testing Products and Services

Dissolution testing allows for the examination and prediction of the in-vitro behavior of pharmaceutical formulations. Drug release behavior of pre-formulations is made possible by the use of specialized dissolution equipment. By dissolution testing, a researcher can simulate the behavior of capsule, bead, and enteric-coated tablets in-vitro.

Important Applications of Dissolution Testing

  • Quality Control
  • Replicating certain mechanisms of in-vitro drug release
  • Determining if drug behavior meets regulatory standards
  • Dissolution simulation when choosing pharmaceutical excipients

Examples of Pharmaceutical Dissolution Equipment

Paddle apparatus dissolution testing is used to simulate tablet behavior in the gastrointestinal tract. The release behavior of implants and transdermal medications can also be tested with dissolution equipment. The reciprocating cylinder dissolution apparatus ("Bio-Dis") is excellent for examining the dissolution behavior of extended release products. Dissolution analysis is key in determining the homogeneity of the final pharmaceutical product. Whether controlled by the bench user or fully automated, the implementation of a dissolution testing protocol is crucial in the final stages of drug development to ensure the efficacy, safety, and marketability of the final compound.
  • Evonik Invests $109 Million in Vancouver Lipid Drug Facility

    Tuesday, September 01, 2026
    Evonik will invest more than 150 million Canadian dollars, or about $109 million, to build a new good manufacturing practice drug-product facility in Vancouver, Canada, expanding its capacity for lipid-based drug delivery products including vaccines, therapeutics and other advanced medicines. read more
  • Andelyn to Scale Manufacturing for Genprex Diabetes Gene Therapy

    Tuesday, September 01, 2026
    Andelyn Biosciences has been selected by Genprex Inc. to support manufacturing scale-up for an adeno-associated virus-based gene therapy program being developed for Type 1 and Type 2 diabetes. read more
  • Samsung Biologics Launches $1.83 Billion Tender Offer for PolyPeptide

    Tuesday, September 01, 2026
    Samsung Biologics has published the formal prospectus for its planned acquisition of PolyPeptide Group AG, offering about $55.70 in cash per share in a transaction that values the Swiss peptide manufacturer’s equity at approximately $1.83 billion. read more
  • CPHI Milan Pharma Awards 2026 Finalists Announced

    Tuesday, September 01, 2026
    Informa Markets has announced the finalists for the CPHI Pharma Awards 2026, recognizing outstanding achievements across companies and individuals pushing the boundaries of science and technology to advance global healthcare. read more
  • When commercialization doesn't follow a standard playbook

    Monday, August 31, 2026
    Low-volume launches. Complex combination products. Market-specific requirements. Unpredictable demand. Commercialization challenges are different for every program, yet many outsourcing models are built for standardization, not flexibility.
    Discover how Ensera helps pharmaceutical companies ... read more
We're sorry, no matching articles were found. Please select different filter options and try your search again.
We're sorry, no matching articles were found. Please select different filter options and try your search again.